SubHero Banner

Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) – New drug approval

July 17, 2018 - Janssen announced the FDA approval of Symtuza (darunavir [DRV]/cobicistat [COBI]/emtricitabine [FTC]/tenofovir alafenamide [TAF]), as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who have no prior antiretroviral (ARV) treatment history or who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable ARV regimen for at least 6 months and have no known substitutions associated with resistance to Prezista® (darunavir) or tenofovir (Vemlidy®, Viread®).

Download PDF